Cargando…

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody

AIM: Anti‐tumour necrosis factor (TNF)‐α drugs are effective treatments for the management of moderate/severe Crohn's disease (CD), but treatment failure is common. In the treatment of paediatric CD, there are no data about the use of a third introduced subcutaneous TNF antibody golimumab. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichler, Judith, Memaran, Nima, Huber, Wolf Dietrich, Aufricht, Christoph, Bidmon‐Fliegenschnee, Bettina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Regular Articles & Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891654/ https://www.ncbi.nlm.nih.gov/pubmed/32781480 http://dx.doi.org/10.1111/apa.15522

Ejemplares similares

Development and validation of the paediatric Carbohydrate Perception Questionnaire (pCPQ), an instrument for the assessment of carbohydrate‐induced gastrointestinal symptoms in the paediatric population
por: Hammer, Johann, et al.
Publicado: (2020)

Golimumab: A Novel Anti-Tumor Necrosis Factor
por: Rossini, Maurizio, et al.
Publicado: (2013)

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
por: Kirkham, Bruce W, et al.
Publicado: (2014)

Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study
por: Conigliaro, Paola, et al.
Publicado: (2021)

Fc-Epsilon-RI, the High Affinity IgE-Receptor, Is Robustly Expressed in the Upper Gastrointestinal Tract and Modulated by Mucosal Inflammation
por: Bannert, Christina, et al.
Publicado: (2012)

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis
por: William, Mridula, et al.
Publicado: (2012)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Relationship Between Abdominal Symptoms and Fructose Ingestion in Children with Chronic Abdominal Pain
por: Hammer, Veronika, et al.
Publicado: (2018)

The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours
por: Cook, A M, et al.
Publicado: (2001)

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa
por: Soto Lopes, Marien Siqueira, et al.
Publicado: (2013)

In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats
por: Veen, A H van der, et al.
Publicado: (1999)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience
por: Cordero-Coma, Miguel, et al.
Publicado: (2014)

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
por: Eberhardson, Michael, et al.
Publicado: (2022)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
por: Smolen, Josef S, et al.
Publicado: (2012)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions
por: de Wilt, J H W, et al.
Publicado: (2000)

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
por: Keystone, E C, et al.
Publicado: (2008)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Safety and clinical efficacy of golimumab in the treatment of arthritides
por: Simsek, Ismail, et al.
Publicado: (2010)

SAT-LB87 Golimumab Induced Thyroiditis
por: Mai, Mo M, et al.
Publicado: (2020)

Two cases of Erythrodermic psoriasis treated with Golimumab
por: Kudsi, Mayssoun, et al.
Publicado: (2022)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
por: Nathoo, Sunina, et al.
Publicado: (2016)

Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
por: Kwak, Min Seob, et al.
Publicado: (2020)

Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes
por: Mracek, T, et al.
Publicado: (2010)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Foscan® (mTHPC) photosensitized macrophage activation: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-α-mediated cytolytic activity
por: Coutier, S, et al.
Publicado: (1999)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study
por: Doz, F, et al.
Publicado: (2001)

Effectiveness of Golimumab in Clinical Management of Patients with Rheumatoid Arthritis
por: Shono, Eisuke
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f4d17spm31h4uen9nftukb8n7i